Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03956056 · ClinicalTrials.gov registry record · Phase 1
Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
A Phase 1 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT03956056 is a Phase 1 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 12 participants.
The verdict
NCT03956056, a Phase 1 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a phase 1 open-label study to evaluate the safety and immunogenicity of a neoantigen peptide vaccine strategy in pancreatic cancer patients following surgical resection and adjuvant chemotherapy. The neoantigen peptide vaccines will incorporate prioritized neoantigens and personalized mesothelin epitopes and will be co-administered with poly-ICLC. The hypothesis of this study is that neoantigen peptide vaccines will be safe and capable of generating measurable neoantigen-specific CD4 and CD8 T cell responses.
Interventions
- DRUG Poly ICLC
- BIOLOGICAL Neoantigen Peptide Vaccine
- PROCEDURE Blood for immune monitoring
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2020-02-13 |
| Est. Completion | 2023-07-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03956056
The ClinicalTrials.gov registry entry for NCT03956056 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Poly ICLC is the first listed.
NCT03956056 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03956056 about?
NCT03956056 is a clinical study titled "Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy". This is a phase 1 open-label study to evaluate the safety and immunogenicity of a neoantigen peptide vaccine strategy in pancreatic cancer patients following surgical resection and adjuvant chemotherapy. The neoantigen peptide vaccines will incorporate prioritized neoantigens and personalized mesoth...
What is the current status of trial NCT03956056?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2020-02-13. Estimated completion is 2023-07-06.
What interventions are being tested in trial NCT03956056?
The interventions under investigation include: Poly ICLC (DRUG), Neoantigen Peptide Vaccine (BIOLOGICAL), Blood for immune monitoring (PROCEDURE).
Who is sponsoring clinical trial NCT03956056?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.